NEWARK — A class of indirect purchasers of GlaxoSmithKline PLC’s Wellbutrin that claimed the drugmaker delayed the entry of generic versions of the antidepressant into the market has been decertified by a federal judge.
U.S. District Judge Mary McLaughlin of the Eastern District of Pennsylvania on June 30 granted Glaxo’s motion to decertify on the basis that the plaintiffs hadn’t provided a mechanism to determine which class members qualified as indirect purchasers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
